The earnings call highlighted strong financial performance and significant advancements in the pipeline, especially in obesity management. However, challenges in the manufacturing of dasiglucagon and the pause in dapiglutide development were noted. The overall sentiment reflects optimism about partnerships and upcoming data readouts, despite some setbacks.
Company Guidance
During the Zealand Pharma Q3 2025 earnings call, the company provided several key updates and forward-looking statements about its ongoing projects and financial performance. The call highlighted Zealand's progress with the petrelintide Phase II ZUPREME-1 trial, anticipating the 42-week top-line data release in the first half of 2026. Additionally, Zealand expects results from the 76-week SYNCHRONIZE-1 Phase III trial for survodutide in the same timeframe. Financially, Zealand reported a revenue of DKK 9.1 billion for the first nine months of 2025, primarily from an upfront payment from its collaboration with Roche, and a cash position of DKK 16.2 billion as of September 30, 2025. The company also narrowed its net operating expenses guidance to between DKK 2 billion and DKK 2.3 billion for the year, following the decision to pause the dapiglutide development. The call emphasized Zealand's strategic focus on the amylin-based therapy petrelintide and its potential to lead in weight management, as well as its collaboration with Roche aimed at redefining future obesity treatments.
Strong Execution and Milestones
Achieved a key milestone in the petrelintide Phase II ZUPREME-1 trial in obesity. Rapidly approaching data from several Phase III trials with survodutide in obesity.
Financial Performance and Position
Revenue for the first 9 months of 2025 was DKK 9.1 billion, primarily from the initial upfront payment from Roche. Cash position increased to DKK 16.2 billion as of September 30, 2025.
Partnerships and Collaborations
Continued momentum in the partnership with Roche. Positive engagement with Boehringer Ingelheim in obesity management.
Pipeline Advancements
Phase III SYNCHRONIZE program of survodutide in obesity consists of 6 trials expected to complete in 2026. Encouraged by the clinical profile of glepaglutide for short bowel syndrome.
Zealand Pharma (ZLDPF) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZLDPF Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2025
$78.72
$80.50
+2.26%
Aug 14, 2025
$53.68
$55.02
+2.50%
May 08, 2025
$68.22
$63.26
-7.27%
Feb 20, 2025
$108.08
$106.34
-1.61%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zealand Pharma (ZLDPF) report earnings?
Zealand Pharma (ZLDPF) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
What is Zealand Pharma (ZLDPF) earnings time?
Zealand Pharma (ZLDPF) earnings time is at Feb 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.